YR-Y declares no competing interests. EG-Y is an employee of Mount Sinai; has received research grants paid to the institution from LEO Pharma, Pfizer, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Aslan, Regeneron, Anaptysbio, Concert, Janssen, Q32Bio, AbbVie, Eli Lilly, Arcutis, and Inmagene Bio; and is a consultant for AbbVie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Artax Biopharma, Astria, Bristol Meyers Squibb, Boehringer Ingelheim, Calliditas, Cara Therapeutics, Celldex, Centrexion Therapeutics Corporation, Connect Biopharm, Coty, DBV Technologies, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Fairmount Funds Management, FL2022–001, Galderma, Gate Bio, Google Ventures, GSK Immunology, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, Novartis Pharmaceuticals, NUMAB Therapeutics AG, Nuvig, OrbiMed Advisors LLC, OTSUKA, Pfizer, Pharmaxis, Pioneering Medicine VII, Proteologix US, RAPT, RayThera, Regeneron Pharmaceuticals, RibonTherapeutics, Rocatinlimab, Sanofi, SATO, Schrödinger, Sitryx, Sun Pharma Advanced Research Company, Takeda, Teva Branded Pharmaceutical Products R&D, UCB, and Ventyx Biosyences.